Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.

By W. Peters, P. Liu, R. Barrett, R. Stock, B. Monk, J. Berek, L. Souhami, Perry Grigsby, W. Gordon, D. Alberts. Journal of Clinical Oncology, 2000

2,245 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, methodology): “In this setting of patients, adjuvant CRT is indicated based on a clinical trial that randomly assigned 268 women IA2, IB and IIA to adjuvant RT with or without chemotherapy (cisplatin–5-fluorouracil) for four courses [33].”
Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer (2011, background): “For cervix cancer, in the past major improvements in regard to loco-regional, distant control and survival has been achieved through simultaneous chemo-radiotherapy which became standard of care in 1999, when five randomized trials were published [14–18].”
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. (2004, background): “These results, combined with consistent findings from four other trials that completed accrual at about the same time [4-7], led to issuance of a clinical alert by the National Institutes of Health [8] and stimulated a dramatic change in the standard of care for many patients with carcinoma of the c”